

Literaturverzeichnis

- 1) Abdel Rahman AA, Khidr SH, Ahmed SM: Evaluation of chloramphenicol- β -cyclodextrin inclusion complex. *Eur J Pharm Biopharm* 1991;37:34-37.
- 2) Ahmed I, Patton TF: Importance of the noncorneal absorption route in topical ophthalmic drug delivery. *Invest Ophthalmol Vis Sci* 1985;26:584-587.
- 3) Algros MP, Angonin R, Delbosc B, Cahn JY, Kantelip B: Danger of systemic cyclosporine for corneal graft. *Cornea* 2002; 21: 613-614.
- 4) Alldredge OC, Krachmer JH: Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates and treatment. *Arch Ophthalmol* 1981;99:599-604
- 5) Allison AC, Almquist SJ, Muller CD et al.: In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. *Transplant Proc* 1991;23 Suppl.2:10-14.
- 6) Allison AC, Eugui EM: Mycophenolat mofetil and its mechanisms of action. *Immunopharmacology* 2000;47:85.
- 7) Althaus C, Dagres E, Reinhard T, Christians U, Sundmacher R: Cyclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high-performance liquid chromatography-electrospray mass spectrometry. *Ger J Ophthalmol* 1996;5:189-194.
- 8) Arancibia-Carcamo CV, Oral HB, Haskard DO, Larkin DF, George AJ: Lipoadenofection-mediated gene delivery to the corneal endothelium. Prospects for modulating graft rejection. *Transplantation* 1998;65:62-67.
- 9) Arentsen JJ: Corneal transplant allograft reaction: possible predisposing factors. *Trans Am Ophthalmol Soc* 1983;81:361-402
- 10) Avunduk AM, Avunduk MC, Erdol H, Kapicioglu Z, Akyol N: Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. *Ophthalmologica* 2001;215:290-293.
- 11) Ayliffe W, Alam Y, Bell EB, McLeod D, Hutchinson IV: Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. *Br J Ophthalmol* 1992;76:602-606.

- 12) Babiolo M, Wilhelm F, Schoch C: In vitro corneal permeation of unoprostone isopropyl (UI) and its metabolism in the isolated pig eye. *J Ocul Pharmacol Ther* 2001;17:159-172.
- 13) Baggesen K, Ehlers N, Lamm LU: HLA-DR/RFLP compatible corneal grafts. *Acta Ophthalmol* 1991;69:229-233.
- 14) Bainbridge JWB, Stephens C, Parsley K et al.: In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector efficient long-term transduction of corneal endothelium and retinal pigment epithelium. *Gene Ther* 2001;8:1665-1668.
- 15) Barker NH, Henderson RPM, Ross CA, Coster DJ, Williams KA: Current australian practice in the prevention and management of corneal allograft rejection. *Clin Exp Ophthalmol* 2000;28:357-360.
- 16) Barron BA: Penetrating keratoplasty. In :Kaufman HE, Barron BA, McDonald MB (eds) *The cornea*, 2nd ed. Boston: Butterworth-Heinemann, 1998:805-845.
- 17) Bartels MC, Otten HG, van Gelderen BE, van der Lelij A: Influence of HLA-A, HLA-B and HLA-Dr matching on rejection of random corneal grafts using corneal tissue for retrospective DNA HLA typing. *Br J Ophthalmol* 2001;85:1341-1346.
- 18) Batchelor JR, Casey TA, Gibbs DC: HLA matching and corneal grafting. *Lancet* 1976;1:551-554.
- 19) Baumgartner I, Mayr WR, Hajek-Rosenmayr A, Grabner G: Differential effect of incompatibilities of the HLA-A and HLA-B locus on the success of corneal transplants. *Klin Monatsbl Augenheilkd* 1988;193:48-51.
- 20) Beato M: Gene regulation by steroid hormones. *Cell* 1989;56:335-344.
- 21) Beekhuis WH, van Rij G, Renardel de Lavalette JGC, Rinkel-van Driel E, Persijn G, d'Amoro J: Corneal graft survival in HLA-A and HLA-B matched transplantations in high-risk cases with retrospective review of HLA-DR compatibility. *Cornea* 1991;10:9-12.
- 22) Beekhuis WH, Bartels M, Doxiadis II, van Rij G: Degree of compatibility for HLA-A and -B affects outcome in high-risk corneal transplantation. *Dev Ophthalmol* 2003;36:12-21.
- 23) Behrens A, Gordon EM, Li L et al.: Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. *Invest Ophthalmol Vis Sci* 2002;43:968-977.
- 24) Belin MW, Bouchard CS, Frantz S, Chielinska J: Topical cyclosporine in high risk corneal transplants. *Ophthalmology* 1989;96:1144-1150.

- 25) Bell KD, Campbell RJ, Bourne WM: Pathology of late endothelial failure: Late endothelial failure of penetrating keratoplasty: Study with light and electron microscopy. *Cornea* 2000;19:40-46.
- 26) Bell TA, Hunnisett AG: Cyclosporin A: tissue levels following topical and systemic administration to rabbits. *Br J Ophthalmol.* 1986;70:852-855.
- 27) Benelli U, Lepri A, Del Tacca M, Nardi M: FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. *J Ocul Pharmacol Ther* 1996;12:425-431.
- 28) Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S: The profile of repeated corneal transplantation. *Ophthalmology* 2001;108:461-469.
- 29) Bertelmann E, Hartmann C, Scherer M, Rieck P: Outcome of rotational keratoplasty: Comparison of endothelial cell loss in autografts versus allografts. *Arch Ophthalmol* 2004;122:1437-1440.
- 30) Bertelmann E, Jaroszewski J, Pleyer U: Corneal allograft rejection: current understanding: 2. Clinical implications. *Ophthalmologica* 2002;216:2-12.
- 31) Bertelmann E, Knapp S, Rieck P, Keipert S, Hartmann C, Pleyer U: Transkornealer-parakornealer Penetrationsweg für lokal applizierte Pharmaka am Auge: Mycophenolat Mofetil als Modellsubstanz. *Ophthalmologie* 2003;100:696-701.
- 32) Bertelmann E, Pleyer U: Immunomodulatory therapy in ophthalmology- Is there a place for topical application? *Ophthalmologica* 2004;218:359-367.
- 33) Bertelmann E, Reinhard T, Pleyer U: Stand der Immunprophylaxe und –therapie bei perforierender Keratoplastik. Eine Umfrage bei Mitgliedern der Sektion Kornea der DOG. *Ophthalmologie* 2003;100:1031-1035.
- 34) Bertelmann E, Ritter T, Vogt K, Reszka R, Hartmann C, Pleyer U: Efficiency of cytokine gene transfer in corneal endothelial cells and organ cultured corneas by liposomal vehicles and recombinant adenovirus. *Ophthalmic Res* 2003;35:117-124.
- 35) Birnbaum F, Reinhard T, Böhringer D, Sundmacher R: Endothelial cell loss after autologous rotational keratoplasty. *Graefes Arch Clin Exp Ophthalmol* 2005;243:57-59.
- 36) Birnbaum F, Reinhard T, Ulbricht T, Haußer J, Sundmacher R: Funktionelle Ergebnisse nach autologer Rotationskeratoplastik. Eine retrospektive Analyse. *Ophthalmologie* 2004;101:54-58.
- 37) Bohm M, Beissert S, Schwarz T, Metze D, Luger T: Bullous pemphigoid treated with mycophenolate mofetil. *Lancet* 1997;349:541.

- 38) Böhnke M, Vogelberg K: HLA Antigene und Keratoplastik. *Fortschr Ophthalmol* 1987;84:519-528.
- 39) Böhringer D, Reindhard T, Spelsberg H, Sundmacher R: Influencing factors on chronic endothelial cell loss characterised in a homogenous group of patients. *Br J Ophthalmol* 2002;86:35-38.
- 40) Boisjoly HM, Tourigny R, Bazin R, Laughrea PA, Dube I, Chamberland G, Bernier J, Roy R: Risk factors of corneal graft failure. *Ophthalmology* 1993;100:1728-1735.
- 41) Boisjoly HM, Dube I, Laughrea PA, Roy R, Bernard PM: Rejection following corneal transplantation. Effects of HLA compatibility of the grafts. *Clin Invest Med* 1989;12:221-223.
- 42) Boisjoly HM, Roy R, Bernard PM, Dube I, Laughrea PA, Bazin R: Association between corneal allograft reactions and HLA compatibility. *Ophthalmology* 1990;97:1689-1698.
- 43) Boisjoly HM, Roy R, Bernard PM, Dubé I, Laughrea PA, Bazin R: HLA-A, B, -DR matching in corneal transplantation. *Ophthalmology* 1986;93:1290-1295.
- 44) Borderie VM, Touzeau O, Bourcier T, Allouch C, Zito E, Laroche L: Outcome of graft central thickness after penetrating keratoplasty. *Ophthalmology* 2005;112:626-633.
- 45) Borel JF: Pharmacology of cyclosporine (Sandimmune). *Pharmacol Rev* 1989;41.
- 46) Borrás T: Recent developments in ocular gene therapy. *Exp Eye Res* 2003;76:643-652.
- 47) Bourne WM, Brubaker RF: A method for ipsilateral rotational autokeratoplasty. *Ophthalmology* 1978;85:1312-1316.
- 48) Bourne WM, Doughman DJ, Lindstrom RL, Kolb MJ, Mindrup EW, Skelnik D: Increased endothelial cell loss after transplantation of corneas preserved by a modified organ-culture technique. *Ophthalmology* 1984;91:285-289.
- 49) Bourne WM, Nelson LR, Hodge DO: Central corneal endothelial cell changes over a ten-year period. *Invest Ophthalmol Vis Sci* 1997;38:779-782.
- 50) Bourne WM, O'Fallon WM: Endothelial cell loss during penetrating keratoplasty. *Am J Ophthalmol* 1978;85:760-766.
- 51) Bourne WM: Chronic endothelial cell loss in transplanted corneas. *Cornea* 1983;2:289-294.

- 52) Bradley BA, Vail A, Gore SM : Negative effects of HLA-DR matching on corneal transplant rejection. *Transplant Proc* 1994;27:1392-1398.
- 53) Bradley BA, Vail A, Gore SM, Rogers CA, Armitage WJ, Nicholls SM, Easty DL: Penetrating keratoplasty in the United Kingdom. An interim analysis of the corneal transplant follow-up study. *Clin Transpl* 1993:293-315.
- 54) Bradshaw JJ, Obritsch WF, Cho BJ, Gregerson DS, Holland EJ: Ex vivo transduction of corneal epithelial progenitor cells using a retroviral vector. *Invest Ophthalmol Vis Sci* 1999;40:230-235.
- 55) Brattstrom C, Tyden G, Sawe J, Herlenius G, Claesson K, Groth CG: A randomized double blind placebo-controlled study to determine safety, tolerance and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. *Transplant Proc* 1996;28:985-986.
- 56) Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C: Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. *Invest Ophthalmol Vis Sci*. 2001;42:90-95.
- 57) Brissette-Storkus CS, Reynolds SM, Lepisto AJ, Hendricks RL: Identification of a novel macrophage population in the normal mouse corneal stroma. *Invest Ophthalmol Vis Sci* 2002;43:2264-2271.
- 58) Budenz DL, Bennett J, Alonso L, Maguire A: In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. *Invest Ophthalmol Vis Sci* 1995;36:2211-2215.
- 59) Buxton JN, Apisson JG, Hoeffle FB: Corticosteroids in 100 keratoplasties. *Am J Ophthalmol* 1969;67:46-51.
- 60) Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman B, Johnson R, Mildvan D, Parekh N, AIDS clinical trials group 334 investigators: Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. *J Acquir Immune Defic Syndr* 2002;29:356-362.
- 61) Cavazzano-Calvo M, Thrasher A, Mavillo F: The future of gene therapy. *Nature* 2004;427:779-781.
- 62) Chanaud NB III., Vistica BP, Eugui E, Nussenblatt RB, Allison AC, Gery I: Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. *Exp Eye Res* 1995;61:429-434.

- 63) Chien DS, Homsy JJ, Gluchowski C, Tang-Liu DD: Corneal and conjunctival/scleral penetration of p-aminocloro AGN 190342, and clonidine in rabbit eyes. *Curr Eye Res* 1990;9:1051-1059.
- 64) Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF: Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. *Invest Ophthalmol Vis Sci* 2002;43:1095-1103.
- 65) Coster DJ, Muehlberg SM, Bartlett CM, Esterman A: Report from the Australian Corneal Graft Registry 1999. Snap Printing: Adelaide, 2000, pp 1-137
- 66) Coster DJ, Williams KA. Immunomodulation for corneal transplantation. In: Pleyer U, Mondino BJ. *Essentials in Ophthalmology. Uveitis and Immunological Disorders.* Springer, Heidelberg/Berlin, 2004; 35-50
- 67) Coster DJ: Mechanisms of corneal graft failure: the erosion of corneal privilege. *Eye* 1989;2:252-262.
- 68) Coupland SE, Penfold PL, Billson FA: Hydrolases of anterior segment tissues in the normal human, pig and rat eye: a comparative study. *Graefes Arch Clin Exp Ophthalmol* 1994;32:182-191.
- 69) Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. *Invest Ophthalmol Vis Sci.* 2004;45:2666-73.
- 70) Davies JB, Ciavatta VT, Boatright JH, Nickerson JM: Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields. *Mol Vision* 2003;9:569-578.
- 71) De Campos AM, Sanchez A, Alonso MJ: Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. *Int J Pharm* 2001;224:159-168.
- 72) Dekaris I, Zhu SN, Dana MR: TNF-alpha regulates corneal Langerhans cell migration. *J Immunol.* 1999;162:4235-9.
- 73) DeRojas Silva MV, Rodriguez-Ares MT, Sanchez-Salorio M, Lamas DMJ, Cuevas Alvarez J, Vila Jato JL, Capeans Tome C: Efficacy of subconjunctival cyclosporine-containing micropheres on keratoplasty rejection in the rabbit. *Graefe's Arch Clin Exp Ophthalmol* 1999;37:840-847.

- 74) Doane MG, Jensen AD, Dohlman CH: Penetration routes of topically applied eye medications. *Am J Ophthalmol* 1978;85:383-386.
- 75) Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. *Transplantation* 2002;73:1310-1317.
- 76) Donish PC, Cavanagh D, Borichoff SA, Dohlman CH: Posterior subcapsular cataract induced by topical corticosteroids following keratoplasty for keratokonus. *Ann Ophthalmol* 1981;13:12-15.
- 77) Doorne van H: Interactions between cyclodextrins and ophthalmic drugs. *Eur J Pharm Biopharm* 1993;39:133-139.
- 78) Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS, et al.: The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. *Transplantation* 1993;56:75-82.
- 79) Fehervari Z, Rayner SA, Oral HB, George AJ, Larkin DF: Gene transfer to ex-vivo stored corneas. *Cornea* 1997;16:459-464.
- 80) Fink N, Stark WJ, Maguire MG, Stulting d, Meyer R, Foulks G, Smith RE, Rapoza P: Effectiveness of histocompatibility matching in high-risk corneal transplantation: a summary of results from the collaborative corneal transplantation studies. *Cesk oftalmol* 1994;50:3-12.
- 81) Foulks GN, Sanfilippo FP, Locascio JA, Mac Queen JM, Dawson DV: Histocompatibility testing for keratoplasty in high-risk patients. *Ophthalmology* 1983;90:239-244.
- 82) Frueh BE, Boehnke M: Prospective, randomized clinical evaluation of Optisol vs organ culture corneal storage media. *Arch Ophthalmol* 2000;118:757-760.
- 83) Frueh BE, Boehnke M: Fujikawa LS, Colvin RB, Bann AK: Expression of HLA-A/B/C and DR locus antigens on epithelial, stromal and endothelial cells of the human cornea. *Cornea* 1982;1:213-218.
- 84) Fulton B, Markham A: Mycophenolate Mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. *Drugs* 1996;51:278-298.
- 85) Gagnon MM, Boisjoly HM, Brunette I, Charest M, Amyot M: Corneal endothelial cell density in glaucoma. *Cornea* 1997;16:314-318.

- 86) Gately MK, Renzetti LM, Magram J et al.: The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. *Annu Rev Immunol* 1998;16:495-521.
- 87) Gene Therapy Clinical Trials Worldwide, provided by the Journal of Gene Medicine, Wiley InterScience 2005.
- 88) George AJT, Arancibia-Carcamo CV, Awad HM et al.: Gene delivery to the corneal endothelium. *Am J Respir Crit Care Med* 2000;162:194-200.
- 89) Gibbs DC, Batchelor JR, Werb A, Schlesinger W, Casey TA: The influence of tissue-type compatibility on the fate of full-thickness corneal grafts. *Trans Ophthalmol Soc UK* 1974;94:101-126.
- 90) Gill TJ, Kunz HW, Misra DN, Hassett ALC: The major histocompatibility complex of the rat. *Transplantation* 1987;43:773-785.
- 91) Gillette TE, Chandler JW, Greiner JV: Langerhans cells of the ocular surface. *Ophthalmology* 1982;89:700-711.
- 92) Goichet-Bonnat L, Chembla P, Pouliquen Y: Cyclosporin A eye drops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results. *J Fr Ophthalmol* 1987;10:213-217.
- 93) Goldblum R: Therapy of rheumatoid arthritis with mycophenolate mofetil. *Clin Exp Rheumatol* 1993;11suppl8:117-119.
- 94) Gore SM, Vail A, Bradley BA, Rogers CA, Easty DL, Armitage WJ: HLA-DR matching in corneal transplantation. *Transplantation* 1995;60:1033-1039.
- 95) Grinyo J; Groth C; Pichlmayr R; Sadek SA; Vanrenterghem Y; Behrend M; Luck R; Moreso F; Peeters J; Rodicio J; Morales J; Albrechtsen D; Fauchald P; Lodge J; Souililou JP; Cantarovich D; Van-Son W; Tegzeva A; Wagner K et al: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995;345:1321-1325.
- 96) Gunduz K, Ozdemir O: Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. *Acta Ophthalmol (Copenh)*. 1994;72:438-442.
- 97) Gupta V, Sahu PK: Topical cyclosporine A in the management of vernal keratoconjunctivitis. *Eye* 2001,15:39-41.
- 98) Hacein-Bey-Abina S, Le Deist F, Carlier F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *New Engl J Med* 2002;346:1185-1193.

- 99) Hahn AB, Foulks GN, Enger C, Fink N, Stark WJ, Hopkins KA, Sanfilippo F: The association of lymphocytotoxic antibodies with corneal allograft rejection in high-risk patients. The collaborative Corneal Transplantation Studies Research Group. *Transplantation* 1995;59:21-27.
- 100) Hamrah P, Zhang Q, Liu Y, Dana MR: Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. *Invest Ophthalmol Vis Sci* 2002;43:639-646.
- 101) Harrison RN, Lippman SS: How steroid hormones work. *Hosp Prac* 1989;24:63-76.
- 102) Hart SL, Arancibia-Carcamo CV, Wolfert MA et al.: Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector. *Hum Gene Ther* 1998;9:575-585.
- 103) He TC, Zhou SB, Dacosta LT, Yu J, Kinzler KW, Vogelstein B: A simplified system for generating recombinant adenoviruses. *Proc Natl Acad Sci USA* 1998;95:2509-2514.
- 104) He YG, Mellon J, Niederkorn JK: The effect of oral immunization on corneal allograft survival. *Transplantation* 1996;61:920-926.
- 105) He YG, Ross J, Niederkorn JY: Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. *Invest Ophthalmol Vis Sci* 1991;32:2723-2728.
- 106) Hess AD, Esa AH, Colombani PM: Mechanism of action of cyclosporine. Effects on cells of the immune system and on subcellular events in T-cell activation. *Transplant Proc* 1988;20:29-40.
- 107) Hikita N, Chan CC, Whitcup SM, Nussenblatt RB, Mochizuki M: Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. *Curr Eye Res* 1995;14:209-214.
- 108) Hikita N, Lopez JS, Chan CC, Mochizuki M, Nussenblatt RB, de Smet MD: Use of topical FK506 in a corneal graft rejection model in Lewis rats. *Invest Ophthalmol Vis Sci* 1997;38:901-909.
- 109) Hill JC, Creemers PC: An adverse matching effect for the HLA-B locus in corneal transplantation. *Transpl Int* 1997;10:145-149.
- 110) Hill JC, Ivey A: Corticosteroids in corneal graft rejection: double versus single pulse therapy. *Cornea* 1994;13:383-388

- 111) Hill JC, Maske R, Watson PG: The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. A preliminary report. *Eye* 1991;5:420-424
- 112) Hill JC: Systemic cyclosporine in high-risk keratoplasty. *Ophthalmology* 1994;101:128-133.
- 113) Hill JC: The use of cyclosporine in high-risk keratoplasty. *Am J Ophthalmol* 1989;107:506-510.
- 114) Hingorani M, Metz D, Lightman SL: Characterisation of the normal conjunctival leukocyte population. *Exp Eye Res* 1997;64:905-912.
- 115) Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S: A randomized, placebo-controlled trial of topical cyclosporine A in steroid-dependent atopic keratoconjunctivitis. *Ophthalmology* 1998;105:1715-1720.
- 116) Hirsch N, Nolle B, Zavazava N, Westphal E, Duncker G, Rochels R, Muller-Ruchholtz W: *Ophthalmologie* 1993;90:174-177.
- 117) Hirst LW, Stark WJ: Clinical specular microscopy of corneal endothelial rejection. *Arch Ophthalmol* 1983;101:1387-1391
- 118) Hoffmann F, Fregel M, Noske W, Bunte S: HLA-B and -DR match reduces the allograft reaction after keratoplasty. *Ger J Ophthalmol* 1994;3:100-104.
- 119) Hoffmann F, Keyserlingk HJ von, Wiederholt M: Die Bedeutung der HLA-Typisierung bei Hornhauttransplantaten mit ungünstiger Prognose unter Cyclosporintherapie. *Fortschr Ophthalmol* 1986;83:542-546.
- 120) Hoffmann F, Kruse HA, Meinhold H, Bedrakis NE, Heimann H, Diamantstein T: Interleukin-2 receptor-targeted therapy by monoclonal antibodies in the rat corneal graft. *Cornea* 1994;13:440-446.
- 121) Hoffmann F, Wiederholt M: Topical cyclosporin A in the treatment of corneal graft reaction. *Cornea* 1986;5:129.
- 122) Hoffmann F, Zhang EP, Pohl T, Kunzendorf U, Wachtlin J, Bulfone-Paus S: Inhibition of corneal allograft reaction by CTLA4-Ig. *Graefes Arch Clin Exp Ophthalmol* 1997;235:535-540.
- 123) Holbach LM, Hinzpeter EN, Naumann GOH: Keratoplastik; in: Naumann GOH (ed) *Pathologie des Auges*; Berlin, Heidelberg: Springer, 1997:642-650.

- 124) Hopkins KA, Magiure MG, Fink NE, Bias WB: Reproducibility of HLA-A, -B, -DR typing using peripheral blood samples: results of retyping in the CCTS. 1992;33:132-141.
- 125) Hudde T, Minassian DC, Larkin DFP: Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. *Br J Ophthalmol* 1999;83:1348-1352.
- 126) Hudde T, Rayner SA, Comer RM et al: Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. *Gene Ther* 1999;6:939-943.
- 127) Hudde T, Rayner SA, De Alwis M et al.: Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. *Cornea* 2000;19:369-373.
- 128) Ing JJ, Ing HH, Nelson LR, Hodge DO, Bourne WM: Ten-year postoperative results of penetrating keratoplasty. *Ophthalmology* 1998;105:1855-1865.
- 129) Inoue K, Amano S, Kimura C, Sato T, Fujita N, Kagaya F, Kaji Y, Oshtsuru T, Araie M: Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. *Jpn J Ophthalmol* 2000;44:302-305.
- 130) Inoue T, Inoue Y, Hayashi I K et al.: Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis. *Cornea* 2002;21:106-110.
- 131) Ippoliti G, Fronterre A: Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. *Transplant proc* 1989;21:3133-3134.
- 132) Irschick E, Miller K, Berger M: Studies of the mechanism of tolerance induced by short term immunosuppression with cyclosporin in high risk corneal allograft recipients: I. Analysis of CTL precursor frequencies. *Transplantation* 1989
- 133) Jonas JB, Rank RM, Budde WM: Autologous ipsilateral rotating penetrating keratoplasty. *Am J Ophthalmol* 2001;131:427-430.
- 134) Jun AS, Larkin DFP: Prospects for gene therapy in corneal disease. *Eye* 2003;17:906-911.
- 135) Kagaya F, Hori J, Kamiya K et al.: Inhibition of murine corneal allograft rejection by treatment with antibodies to CD80 and CD86. *Exp Eye Res* 2002;74:131-139.

- 136) Kalbheim-Gapp EM: *TE Dermatologie* 1998;8:151-152.
- 137) Kamata Y, Tanabe A, Kanaji A et al.: Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. *Gene Ther.* 2003;10:406-414.
- 138) Kaswan RL: Intraocular penetration of topically applied cyclosporine. *Transplant Proc.* 1988;20(Suppl 2):650-655.
- 139) Keown P; Hayry P; Mathew T; Morris P; Stiller C; Barker C; Carr L; Landsberg D; Hardie I; Rigby R; Isoniemi H; Morris P; Gray D; Belitsky P; McDonald A; Clarkson A; Barratt L; Buchholz B; Walker R: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996;61:1029-1037.
- 140) Khaireddin R, Wachtlin J, Hopfenmüller W, Hoffmann F: HLA-A, HLA-B and HLA-Dr matching reduces the rate of corneal allograft rejection. *Graefes Arch Clin Exp Ophthalmol* 2003;241:1020-1028.
- 141) Khodadoust AA, Silverstein AM: Transplantation and rejection of individual cell layers of the cornea. *Invest Ophthalmol* 1969;8:180-195.
- 142) Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD: CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. *Invest Ophthalmol Vis Sci.* 2001;42:1285-292.
- 143) King, WJ, Comer, RM, Hudde, T, Larkin, DF, George, AJ: Cytokine and chemokine expression kinetics after corneal transplantation. *Transplantation* 2000;70:1225-1233.
- 144) Kirk AD, Harlan DM: The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? *JAMA* 1999;282:1076-1082.
- 145) Kirklin JK, Bourge RC, Naftel DC, Morrow WR, Deierhoi MH, Kauffman RS, White-Williams C, Nomberg RI, Holman WL, Smith DC Jr: Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. *J Heart Lung Transplant* 1994;13:444-50.

- 146) Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL: Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. *J Am Acad Dermatol*. 1997;37:445-9.
- 147) Klebe S, Stirling JW, Williams KA: Corneal endothelial cell nuclei are damaged after DNA transfer using a gene gun. *Clin Exp Ophthalmol* 2000;28:58-59.
- 148) Klebe S, Sykes PJ, Coster DJ, Bloom DC, Williams KA: Gene transfer to ovine corneal endothelium. *Clin Exp Ophthalmol* 2001;29:316-322.
- 149) Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA: Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine interleukin 10. *Transplantation* 2001;71:1214-1220.
- 150) Klein J: Natural history of the major histocompatibility complex. New York, J. Wiley & Sons, Inc 1987.
- 151) Knapp S, Bertelmann E, Hartmann C, Pleyer U, Keipert S: Intraocular availability of topically applied Mycophenolate mofetil in rabbits. *J Ocul Pharmacol Ther* 2003;19:181-192.
- 152) Knop N, Knop E: Conjunctival-associated lymphoid tissue in the human eye. *Invest Ophthalmol Vis Sci* 2000;41:1270-1279.
- 153) Koay PY, Lee WH, Figueiredo FC: Opinions on risk factors and management of corneal graft rejection in the United Kingdom. *Cornea*. 2005;24:292-296.
- 154) Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valentine H: A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. *Transplantation* 1998;66:507-15.
- 155) König Merediz SA, Zhang EP, Wittig B, Hoffmann F: Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. *Graefes Arch Clin Exp Ophthalmol* 2000;238:701-707.
- 156) Krachmer JH, Alldredge OC: Subepithelial infiltrates: a probable sign of corneal transplant rejection. *Arch Ophthalmol* 1978;96:2234-2237.
- 157) Kraupa E: Transposition durch Lappendrehung; eine neue Methode der Keratoplastik. *Zbl. Augenh* 1914;38:132.

- 158) Kulkarni PS: Steroidal and nonsteroidal drugs in endotoxin-induced uveitis. *J Ocul Pharmacol Ther* 1994;10:329-334.
- 159) Kunert KS, Tisdale AS, Gipson IK: Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. *Arch Ophthalmol*. 2002;120:330-337. Erratum in: *Arch Ophthalmol* 2002;120:1099.
- 160) Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. *Arch Ophthalmol*. 2000;118:1489-1496.
- 161) Lai CM, Brankov M, Zaknick T et al.: Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. *Hum Gene Ther* 2001;12:1299-1310.
- 162) Lai CM, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE: Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense inhibition of VRGF RNA. *Exp Eye Res* 2002;75:625-34.
- 163) Lam DS, Wong AK, Tham CC, Leung AT: The use of combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection. A preliminary study. *Eye* 1998;12:615-618.
- 164) Land W: *Immunosuppressive Therapie Band 3*, Georg ThiemeVerlag Stuttgart, New York 2005: S:28-48.
- 165) Langenbacher A, Seitz B, Nguyen NX, Naumann GOH: Corneal endothelial cell loss after nonmechanical penetrating keratoplasty depends on diagnosis: a regression analysis. *Graefes Arch Clin Exp Ophthalmol* 2002;240:387-392.
- 166) Larkin DFP, Alexander RA, Cree IA: Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. *Eye* 1997;11:68-74.
- 167) Larkin DFP, Oral HB, Ring CJA, Lemoine NR, George AJT: Adenovirus-mediated gene delivery to the corneal endothelium. *Transplantation* 1996;61:363-370.
- 168) Larkin F, Lightman S: Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. *Ophthalmology* 1999;106:370-4.
- 169) Lee VHL, Chang SC, Oshiro CM, Smith RE: Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. *Curr Eye Res* 1985;4:1117-1125.

- 170) Lee VHL, Iimoto DS, Takemoto KA: Subcellular distribution of esterases in the bovine eye. *Curr Eye Res* 1983;2:869-876.
- 171) Leibovitz HM, Kupfermann A: Kinetics of topically administered prednisolone acetate. *Arch Ophthalmol* 1976;94:1387-1389.
- 172) Leibovitz HM: Management of inflammation in the cornea and conjunctiva. *Ophthalmology* 1980;87:753-757.
- 173) Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR: Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive cells derived from MHC class II-negative grafts. *J Exp Med* 2002;195:259-268.
- 174) Loftsson T, Frithriksdottir H, Stefansson E, Thorisdottir S, Guthmundsson O, Sigthorsson T: Topically effective ocular hypotensive acetazolamide and ethoxzolamide formulations in rabbits. *J Pharm Pharmacol.* 1994;46:503-504.
- 175) Loftsson T, Järvinen T: Cyclodextrins in ophthalmic drug delivery. *Adv Drug Deliv Rev* 1999;36:59-79.
- 176) Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A: Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies research group. *Ophthalmology* 1994;101:1536-1547.
- 177) Marshall E: Gene therapy death prompts review of adenovirus vector. *Science* 1999;286:2244-2245.
- 178) Martin CF, DeBarge LR; Nussenblatt RB, Chan CC, Roberge FG: Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. *J Immunol* 1995;154:922-927.
- 179) Masuda I, Matsuo T, Yasuda T, Matsuo N: Gene transfer with liposomes to the intraocular tissues by different routes of administration. *Invest Ophthalmol Vis Sci* 1996;37:1914-1920.
- 180) Matsuda M, Manabe R: The corneal endothelium following autokeratoplasty. A case report. *Acta Ophthalmol (Copenh)* 1988;66:54-57.
- 181) Mayer DJ, Daar AS, Casey TA, Fabre JW: Localization of HLA -A, B, C and HLA-DR antigens in the human cornea: practical significance for grafting technique and HLA typing. *Transplant Proc* 1983;15:126-129

- 182) Mayer K, Reinhard T, Reis A, Bohringer D, Sundmacher R: FK506 ointment 0.1% - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. *Klin Monatsbl Augenheilkd* 2001;218:733-736.
- 183) McDonnell PJ, Falcon MG: Rotational autokeratoplasty. *Eye* 1989;3:576-580.
- 184) Milani J, Pleyer U, Dukes A, Chou HJ, Lutz S, Rückert D, Schmidt KH, Mondino BJ: Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. *Ophthalmology* 1993;100:890-896.
- 185) Miller K, Huber C, Niederwieser D, Göttinger W: Successful engraftment of high-risk corneal allografts with short-term immuno-suppression with cyclosporine. *Transplantation* 1988;45:651-653.
- 186) Mills RA, Jones DB, Winkler CR, Wallace GW, Wilhelmus KR: Topical FK506 prevents experimental corneal allograft rejection. *Cornea* 1995;14:157-160.
- 187) Mohan RR, Sschultz GS, Hong JW, Moham RR, Wilson SE: Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. *Exp Eye Res* 2003;76:373-383.
- 188) Moore JE, McMullen TCB, Campbell IL et al.: The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. *Invest Ophthalmol Vis Sci* 2002;43:2905-2915.
- 189) Moore KW, O'Garra A, De Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. *Annu Rev Immunol* 1993;11:165-190.
- 190) Morris RE, Hunag X, Gregory CR, Billingham ME, Rowan R, Shorthouse R: Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. *Transplant Proc* 1995;27:2068-2069.
- 191) Morris RE, Shorthouse R: A study of the contrasting effects of cyclosporine FK506 and rapamycin on suppression of allograft rejection. *Transplant Proc* 1990;22:1638-1641.
- 192) Mortola E, Endo Y, Ohno K, Watari T, Tsujimoto H, Hasegawa A: The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. *Vet Res Commun* 1998;22:553-563.

- 193) Mosteller MW, Gebhardt BM, Hamilton AM, Kaufman HE: Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum. *Arch Ophthalmol*. 1985;103:101-102.
- 194) Müller A, Zhang EP, Sschroff M, Wittig B, Hoffmann F: Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. *Graefes Arch Clin Exp Ophthalmol* 2002;240:851-859.
- 195) Munkhbat B, Hagihara M, Shimazaki J, Kanai N, Morita N, Gansuud B, Kato S, Tsubota K, Tsuji K: the impact of HLA-A matching in corneal transplantation. *Tokai J exp clin Med* 1999;24:63-71.
- 196) Murthy RC, McFarland TJ, Yoken J et al.: Corneal transduction to inhibit angiogenesis and graft failure. *Invest Ophthalmol Vis Sci* 2003;44:1837-1842.
- 197) Murthy S, Bansal AK, Sridhar MS, Rao GN: Ipsilateral rotational autokeratoplasty. An alternative to penetrating keratoplasty in nonprogressive central corneal scars. *Cornea* 2001;20:455-457.
- 198) Musch DC, Meyer RF, Sugar A: Predictive factors for endothelial cell loss after penetrating keratoplasty. *Arch Ophthalmol* 1993;111:80-83.
- 199) Musch DC, Schwartz AE, Fitzgerald-Shelton K, Sugar A, Meyer RF: The effect of allograft rejection after penetrating keratoplasty on central endothelial cell density. *Am J Ophthalmol* 1991;111:739-742
- 200) Naacke HG, Borderie VM, Bourcier T, Touzou O, Moldovan M, Laro M: Outcome of corneal transplantation rejection. *Cornea* 2001;20:350-353.
- 201) Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE: The IL-4 receptor: signaling mechanisms and biologic functions. *Annu Rev Immunol* 1999;7:701-38.
- 202) Newman DK, Isaacs JD, Watson PG, Meyer PA, Hale G, Waldmann H: Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. *Eye* 1995;9:564-569.
- 203) Nguyen NX, Langenbacher A, Seitz B, Kühle M, Naumann GOH: Impact of increased intraocular pressure on long-term corneal endothelial cell density after penetrating keratoplasty. *Ophthalmologica* 2002;216:40-44.
- 204) Nicholls SM, Bradley BB, Easty DL: Effect of mismatches for major histocompatibility complex and minor antigens on corneal graft rejection. *Invest Ophthalmol Vis Sci* 1991;32:2729-2734.

- 205) Nickerson P, Steiger J, Zheng X et al.: Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? *Transplantation* 1997;63:489-494.
- 206) Niederkorn JY: Mechanisms of corneal graft rejection. *Cornea* 2001;20:675-679.
- 207) Niederkorn JY: The immune privilege of corneal allografts. *Transplantation* 1999;67:1503-1508.
- 208) Nishi M, Herobrt CP, Matsubara M, Morishita Y, Nishimura M, Nieda M, Mori S, Mochizuki M: Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. *Invest Ophthalmol Vis Sci* 1993;34:2477-2486.
- 209) Nishimura JK, Hodge DO, Bourne WM: Initial endothelial cell density and chronic endothelial cell loss rate in corneal transplants with late endothelial failure. *Ophthalmology* 1999;106:1962-1965.
- 210) Nussenblatt RB, Palestine AG: Cyclosporine: immunology, pharmacology and therapeutic uses. *Surv Ophthalmol* 1986;31:159-169.
- 211) Ohia EO, Mancino M, Kulkarni RS : Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits. *J Ocul Pharmacol Ther* 1992;8:295-307.
- 212) Okada K, Sakata H, Minamoto A, Fujihara M: Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. *Ophthalmologica* 1996;210:175-179.
- 213) Ollivier FJ, Brooks DE, Komaromy AM, Kallberg ME, Andrew SE, Sapp HL, Sherwood MB, Dawson WW: Corneal thickness and endothelial cell density measured by non-contact specular microscopy and pachymetry in rhesus macaques (*Macaca mulatta*) with laser-induced ocular hypertension. *Exp Eye Res* 2003;76:671-677.
- 214) Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ : Rapamycin inhibits corneal allograft rejection and neovascularization. *Arch Ophthalmol* 1994; 112:1471-1475.
- 215) Opelz G: Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. *Transplantation* 1994;58:443-446
- 216) Oral HB, Larkin DF, Fehervari Z, Byrnes AP, Rankin AM, Haskard DO, Wood MJ, Dallman MJ, George AJ: Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. *Gene Ther* 1997;4:639-647

- 217) Oshima Y, Sakamoto T, Hisatomi T et al.: Targeted gene transfer to corneal stroma in vivo by electric pulses. *Exp Eye Res* 2002;74:191-198.
- 218) Ozdemir O: A prospective study of histocompatibility testing for keratoplasty in high-risk patients. *Br J Ophthalmol* 1986;70:183-186.
- 219) Patel SV, Hodge DO, Bourne WM: Corneal endothelium and postoperative outcomes 15 years after penetrating keratoplasty. *Am J Ophthalmol* 2005;139:311-319
- 220) Pepose JS, Leib DA: Herpes simplex viral vectors for therapeutic gene delivery to ocular tissues. Recent breakthroughs in the molecular genetics of ocular diseases. *Invest Ophthalmol Vis Sci* 1994;35:2662-2666.
- 221) Perry HD, Donnenfeld ED, Acheampong A, Kanellopoulos AJ, Sforza d'Aversa G, Wallerstein A, Stern M: Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. *Ophthalmology* 1998;105:1550-1556.
- 222) Perry HD, Donnenfeld ED, Kanellopoulos AJ, Grossman GA: Topical cyclosporin A in the management of postkeratoplasty glaucoma. *Cornea* 1997;16:284-288.
- 223) Pfau B, Kruse FE, Rohrschneider K, Zorn M, Fiehn W, Burk ROW, Voelcker HE: Comparison between local and systemic cyclosporine concerning the concentration in conjunctiva, aqueous humor and blood. *Ophthalmologie* 1995;92:833-839.
- 224) Piccotti JR, Chan SY, Vanbuskirk AM, Eichwald EJ, Bishop DK: Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? *Transplantation* 1997;63:619-624.
- 225) Pleyer U (Hrsg.): Immunobiology and prevention of allograft rejection after experimental keratoplasty. *Aeolus, Buren* 1996:Seiten 22-23.
- 226) Pleyer U, Bertelmann E, Rieck P, Hartmann C, Volk HD, Ritter T: Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. *Graefes Arch Clin Exp Ophthalmol* 2002;238:531-536.
- 227) Pleyer U, Bertelmann E, Rieck P, Hartmann C: Outcome of penetrating keratoplasty in rheumatoid arthritis. *Ophthalmologica* 2002;216:249-255

- 228) Pleyer U, Bertelmann E, Volk HD, Hartmann C, Ritter T: Gene transfer of (viral) interleukin-10 but not interleukin-4 prolongs allograft survival in experimental keratoplasty. *Invest Ophthalmol Vis Sci* 2000;41(suppl):543.
- 229) Pleyer U, Dannowski H, Volk HD, Ritter T: Corneal allograft rejection: Current understanding, Part 1. *Ophthalmologica* 2001;215:245-262.
- 230) Pleyer U, Dannowski H: Delivery of genes via liposomes to corneal endothelial cells. *Drug News Perspect* 2002;15:283-289.
- 231) Pleyer U, Groth D, Hinz B, Keil O, Bertelmann E, Rieck P, Reszka R: Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. *Exp Eye Res* 2001;73:1-7
- 232) Pleyer U, Lutz S, Jusko WJ, Nguyen K, Narawane M, Rückert D, Mondino BJ, Lee VHL: Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. *Invest Ophthalmol Vis Sci* 1993;34:2737-2742.
- 233) Pleyer U, Milani JH, Dukes A, Chou J, Mondino BJ: Effect of liposome encapsulated anti CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. *Invest Ophthalmol Vis Sci* 1995;35:52-61.
- 234) Pleyer U, Raphael B, Kosmidis P, Ryffel B, Thiel HJ: Verteilung von Cyclophilin in okulären Geweben. *Ophthalmologe* 1993;90:118.
- 235) Pleyer U, Ritter T: Gene therapy in immune mediated diseases of the eye. *Prog Retin Eye Res* 2003;22:277-293.
- 236) Pleyer U, Steuhl KP, Weidle EG, Lisch W, Thiel HJ: Corneal graft rejection: Incidence, manifestation, and interaction of clinical subtypes. *Transplant Proc* 1992;24:2034-2037.
- 237) Pleyer U, Weidle EG, Lisch W, Steuhl KP, Möhrle C, Richter U, Zierhut M, Selbmann HK: Klinische Verlaufsformen immunologischer Transplantatreaktionen nach perforierender Keratoplastik. *Fortschr Ophthalmol* 1990;87:14-19.
- 238) Pleyer U, Weidle EG, Thiel HJ: The use of cyclosporine in high-risk keratoplasty. *Am J Ophthalmol* 1989;108:467-468.
- 239) Qian Y, Boisgerault F, Benichou G, Dana MR: Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants. *Invest Ophthalmol Vis Sci* 2001;42:987-994.

- 240) Qian Y, Dana MR: Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants. *Cornea* 2002;21:592-597.
- 241) Qian Y, Dana MR: Molecular mechanisms of immunity in corneal allotransplantation and xenotransplantation. *Expert Rev Mol Med* 2001:1-21.
- 242) Rajagopalan N, Chen SC, Chow WS: A study of the inclusion complex of amphotericin B in the presence of β -cyclodextrin. *Int J Pharm* 1986;29:161-168.
- 243) Rayner SA, Gallop JL, George AJT, Larkin DFP: Distribution of integrins α V β 5, α V β 3 and α V in normal human cornea: possible implications in clinical and therapeutic adenoviral infection. *Eye* 1998;12:273-277.
- 244) Rayner SA, Larkin DF, George AJ: TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. *Invest Ophthalmol Vis Sci* 2001;42:1568-73.
- 245) Reer O, Bock TK, Müller BW: In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product Voltaren Ophtha. *J Pharm Sci*;1994;83:1345-1349.
- 246) Reinhard T, Böhringer C, Enczmann J, Kogler G, Mayweg S, Sundmacher R: HLA class I and II matching improves prognosis in penetrating normal-risk keratoplasty. *Dev Ophthalmol* 2003;36:42-49.
- 247) Reinhard T, Böhringer D, Enczmann J, Kogler G, Wernet P, Böhringer S, Sundmacher R: HLA class I/II matching and chronic endothelial cell loss in penetrating normal risk keratoplasty. *Acta Ophthalmol Scand* 2004;82:13-18.
- 248) Reinhard T, Böhringer D, Hüschen D, Sundmacher R: Chronischer Endothelzellverlust des Transplantats nach perforierender Keratoplastik: Einfluss der Migration von Endothelzellen vom Transplantat zur Wirtshornhaut. *Klin Monatsbl Augenheilkd* 2002;219:410-416.
- 249) Reinhard T, Böhringer D, Sundmacher R: Accelerated chronic endothelial cell loss after penetrating keratoplasty in glaucoma eyes. *Journal of Glaucoma* 2001;10:446-451.
- 250) Reinhard T, Mayweg S, Reis A, Sundmacher R: Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. *Transpl Int* 2005;18:193-197.

- 251) Reinhard T, Sundmacher R, Godehard E, Heering P: Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor. *Ophthalmologie* 1997;94:496-500.
- 252) Reinhard T, Sundmacher R: Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty: a pilot study. *Transpl Int* 2002;15:81-88.
- 253) Reinhard T, Moller M, Sundmacher R: Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A: *Cornea* 1999;18:645-651.
- 254) Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviehhaus H, Engelmann K, Voiculescu A, Godehardt E, Sundmacher R: Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. *Transpl Int* 2005;18:70370-8.
- 255) Reis A, Megahed M, Reinhard T, Godehard E, Braunstein C, Sundmacher R: Synergism of RAD and cyclosporine A in prevention of acute rat corneal allograft rejection: *Cornea* 2002;21:81-84.
- 256) Reis A, Megahed M, Reinhard T, Godehardt E, Spelsberg H, Braunstein C, Sundmacher R: Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. *Transplantation* 2000;70:1397-1407.
- 257) Reis A, Reinhard T, Sundmacher R, Braunstein C, Godehard E: Effect of mycophenolate mofetil, cyclosporine A and both in combination in a murine corneal graft rejection model. *Br J Ophthalmol* 1998;82:700-703.
- 258) Reis A, Reinhardt T, Voiculescu A, Kutkuhn B, Godehardt E: Effect of mycophenolate mofetil versus Cyclosporin A in high-risk keratoplasty patients: a prospective randomized clinical trial. *Br J Ophthalmol* 1999;83:1268-1271.
- 259) Rinne JR, Stulting RD: Current practice in the prevention and treatment of corneal allograft rejection. *Cornea* 1992;11:326-328.
- 260) Ritter T, Gong N, Pleyer U: .Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases? *Br J Ophthalmol*. 2005;89:648-9

- 261) Ritter T, Vogt K, Rieck P et al.: Adenovirus-mediated gene transfer of interleukin-4 to corneal endothelial cells and organ cultured corneas leads to high IL-4 expression. *Exp Eye Res* 1999;69:563-568.
- 262) Roberge FG, Xu D, Chan CC, de Smet MD, Nussenblatt RB, Chen H: Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. *Curr Eye Res* 1993;12:197-203.
- 263) Robert PY, Delbose B, Preux PM, Monnot PH, Drouet M, Peyronet P, Adenis JP: treatment with cyclosporine A, with low doses, in high-risk penetrating keratoplasties. A bicentric study of 90 cases. *J Fr Ophthalmol* 1997;20:507-514.
- 264) Robert PY, Liekfeld A, Metzner S, Ranger-Rogez S, Adenis JP, Denis F, Hartmann C, Pleyer U. Specific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors. *Graefes Arch Clin Exp Ophthalmol*. 2005; 26:1-6.
- 265) Roy R, Boisjoly HM, Wagner E, Langlois A, Bernard PM, Bazin R, Laughrea PA, Dube I: Pretransplant and posttransplant antibodies in human corneal transplantation. *Transplantation* 1992;54:463-467.
- 266) Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U: Systemic cyclosporin A in high failure risk, repeated corneal transplantation. *Br J Ophthalmol* 2002;86:988-992.
- 267) Ruusuvaara P: Histocompatibility and corneal graft endothelium. *Acta Ophthalmol* 1979;57:968-981.
- 268) Sakamoto T, Oshima Y, Nakagawa K, Ishibashi T, Inomata H, Sueishi K: Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness. *Hum Gene Ther* 1999;10:2551-2557.
- 269) Sall K, Stevenson OD, Mundorf TK, Reis BL and CsA phase 3 study group: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. *Ophthalmology* 2000;107:631-639.
- 270) Sanfilippo FP, Mac Queen JM, Vaughn WK, Foulks GN: Reduced graft rejection with good HLA-A and -B matching in high risk corneal transplantation. *N Engl J Med* 1986;315:29-35.

- 271) Sano Y, Osawa H, Sotozono C, Kinoshita S: Cytokine expression during orthotopic corneal allograft rejection in mice. *Invest Ophthalmol Vis Sci* 1998;39:1953-1957.
- 272) Sasamoto YA, Hirose s, Ohno S, Onoe K, Matsuda H: Topical application of ciclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis. *Ophthalmologica* 1991;203:118-125.
- 273) Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF: Penetration into the anterior chamber via the conjunctival/scleral pathway. *J Ocul Pharmacol Ther* 1997;13:41-59.
- 274) Schoenwald RD, Ward R: Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. *J Pharm Sci* 1978;67:786-788.
- 275) Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. *Clin Biochem* 1998;31:335-340.
- 276) Seitz B, Baktanian E, Gordon EM, French Anderson W, Labree L, McDonnell PJ: Retroviral vector-mediated gene transfer into keratocytes: in vitro effects of polybrene and protamine sulphate. *Graefes Arch Clin Exp Ophthalmol* 1998;236:602-612.
- 277) Seitz B, Langenbucher A, Nguyen NX, Kus MM, Kuchle M, Naumann GOH: Graft endothelium and thickness after penetrating keratoplasty, comparing mechanical and excimer laser trephination: a prospective randomised study. *Graefes Arch Clin Exp Ophthalmol* 2001;239:12-17.
- 278) Severin M: Immunreaktionen nach Keratoplastik. *Klin Mbl Augenheilk* 1986;188:00-208.
- 279) Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE: The side effects of FK506 in humans. *Transplant Proc* 1990;22:41-43.
- 280) Sherif Z, Pleyer U: Corticosteroids in ophthalmology: past-present-future. *Ophthalmologica* 2002;216:305-315.
- 281) Shewring L, Collins L, Lightman SL, Hart S, Gustafsson K, Fabre JW: A nonviral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins. *Transplantation* 1997;64:763-769.

- 282) Shiraishi A, Converse RL, Liu CY, Zhou F, Kao CW, Kao WW: Identification of the cornea-specific keratin 12 promoter by in vivo particle-mediated gene transfer. *Invest Ophthalmol Vis Sci* 1998;39:2554-2561.
- 283) Siefert B, Pleyer U, Müller M, Hartmann C, Keipert S: Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide. *J Ocul Pharmacol Ther* 1999;15: 429-438.
- 284) Sigal NH, Dumont FJ: Cyclosporin A, FK506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. *Ann Rev Immunol* 1992;10:519-560.
- 285) Sloper CM, Powell RJ, Dua HS: Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. *Ophthalmology* 2001;108:1838-1844.
- 286) Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. *Transplantation* 1995;60:225-232.
- 287) Sollinger HW, Belzer FO, Deierhoi MH, et al.: RS-61443 (mycophenolate mofetil): A multicenter study for refractory kidney transplant rejection. *Ann Surg* 1992;216:513-519.
- 288) Somia N, Verma IM: Gene therapy: trials and tribulations. *Nat Rev Genet* 2000;1:91-99.
- 289) Stamer L, Bohnke M, Vogelberg K, Arndt R: Tissue levels of locally applied cyclosporin A in the rabbit eye. *Fortschr Ophthalmol*. 1989;86:540-542.
- 290) Stechschulte SU, Jousseaume AM, Von Recum HA et al.: Rapid ocular angiogenic control via naked DNA delivery to the cornea. *Invest Ophthalmol Vis Sci* 2001;42:1975-1979.
- 291) Streilein JW, Arancibia-Carcamo C, Osawa H: The role of minor histocompatibility alloantigens in penetrating keratoplasty. *Dev Ophthalmol* 2003;36: 74-88.
- 292) Sugar A, Bokosky JE, Meyer RF: a randomized trial of topical corticosteroids in epithelial healing after keratoplasty. *Cornea* 1993;3:268-271.
- 293) Sundmacher R, Reinhard T, Heering P: Six years experience with systemic Cyclosporin A prophylaxis in high risk perforating keratoplasty patients. *German J Ophthalmol* 1992;1:432-436.

- 294) Sundmacher R, Reinhard T: Cyclosporin A in high risk perforating keratoplasty. Zierhut M, Pleyer U, Thiel HJ (eds) Immunology of corneal transplantation. Aeolus, Amsterdam; 1994:233-238.
- 295) Takahashi K, Luo T, Saishin Y et al.: Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 2002;13:1305-1316.
- 296) Takahashi N, Hayano T, Suzuki M: Peptidyl-propyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989;337:473.
- 297) Tan PH, King WJ, Chen D et al.: Transferrin receptor-mediated gene transfer to the corneal endothelium. Transplantation 2001;71:552-560.
- 298) Tan PH, Manunta M, Ardjomand N et al.: Antibody targeted gene transfer to endothelium. J Gene Med 2003;5:311-323.
- 299) Tanelian D, Barry MA, Johnston SA, Le T, Smith G: Controlled gene gun delivery and expression of DNA within the cornea. BioTechniques 1997;23:484-488.
- 300) Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG: Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 1994;13:571-82.
- 301) Tchah H, Lim B: Effect of FK 506 on the cornea: use of topical FK 506 in corneal transplantation in a guinea pig-rat model. Korean J Ophthalmol 1999;13:71-77.
- 302) Thali M: Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity. Mol Med Today 1995;1:287-291.
- 303) The collaborative corneal transplantation studies research group CCTS: Effectiveness of histocompatibility matching in high risk corneal transplantation. Arch Ophthalmol 1992;110:1392-1403.
- 304) Thiel MA, Coster DJ, Williams KA: The potential of antibody-based immunosuppressive agents for corneal transplantation. Immunol Cell Biol 2003;81:93-105.
- 305) Thiel MA, Ross CA, Coster DJ: Corneal allograft rejection: has the time come for intravenous pulsed methylprednisolone? A debate. Clin Exp Ophthalmol 2000;28:398-404.
- 306) Thiel MA, Takano T, Hawksworth N, Coster DJ, Williams KA: Low-dose, short-term treatment with anti-CD4 monoclonal antibody prolongs corneal allograft survival. Transplant Proc 2000;33:635-636.

- 307) Thompson JF, Chalmers DH, Wood RF, Kirkham SR, Morris PJ: Sudden death following high-dose intravenous methyl-prednisolone. *Transplantation* 1983;36:594-596.
- 308) Thompson P, Xu D, Brunette I, Chen H: Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection. *Transplantation Proc* 1998;30:1033-1035.
- 309) Torres PF, De Vos AF, Van der Gaag R, Martins B, Kijlstra A: Cytokine mRNA expression during experimental corneal allograft rejection. *Exp Eye Res* 1996;63:453-461.
- 310) Treesler PA, Foulks GN, Sanfilippo F: The expression of HLA antigens on human corneal tissue. *Am J Ophthalmol* 1984;98:763-772.
- 311) Tsai ML, Chen SL, Chou PI, Wen LY, Tsai RJF, Tsao YP: Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium. *Invest. Ophthalmol Vis Sci* 2002;43:751-757.
- 312) Tsubota K, Inoue H, Ando K, Ono M, Yoshino K, Saito I: Adenovirus-mediated gene transfer to the ocular surface epithelium. *Exp Eye Res* 1998;67:531-538.
- 313) Tuft SJ, Coster DJ: The corneal endothelium. *Eye* 1990;4:389-424.
- 314) Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL: Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. *Cornea*. 2000;19:492-496.
- 315) Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ: Clinical and surgical factors influencing corneal graft survival, visual acuity and astigmatism. *Ophthalmology* 1996;103:41-49.
- 316) Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ: Influence of donor and histocompatibility factors on corneal graft outcome. *Transplantation* 1994;58:1210-1216.
- 317) van Rooij J, Rijneveld WJ, Remeijer L, Volker-Dieben HJ, Eggink CA, Geerards AJ, Mulder PG, Doornenbal P, Beekhuis WH: Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial. *Ophthalmology* 2003;110:1916-1919
- 318) Vasco-Posada J: Ipsilateral autokeratoplasty. *Am J Ophthalmol* 1967;64:717-721.

- 319) Verma N, Melengas S, Garap JA: Ipsilateral rotational autokeratoplasty for the management of corneal opacities. *Aus N Z J Ophthalmol* 1999;27:21-25.
- 320) Völcker-Dieben H, Claas FHJ, Schreuder GMT, Schipper RF, Pels E, Persijn GG, Smits J, D'Amero J: Beneficial effects of HLA-DR matching on the survival of corneal allografts. *Transplantation* 2000;70:640-648.
- 321) Völcker-Dieben HJ, D'Amero J, Kruit PJ, De Lange P: Interaction between prognostic factors for corneal allograft survival. *Transplant Proc* 1989;21:3135-3138.
- 322) Völcker-Dieben HJ, Kok-van Alphen CC, Landsberger Q, Persijn GG: Advances and disappointments, indications and restrictions regarding HLA-matched corneal grafts in high-risk cases. *Doc Ophthalmol* 1982;46:219-226.
- 323) Wachtlin J, Khairuddin R, Hoffmann F: Tissue typing in perforating corneal transplantation. *Ophthalmologe* 2003;100:1021-1030
- 324) Wang X, Appukuttan B, Ott S et al.: Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. *Gene Ther* 2000;7:196-200.
- 325) Whitcup SM, Pleyer U, Lai JC, Lutz S, Mochizuki M, Chan CC: Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. *Ocul Immunol Inflamm* 1998;6:51-56.
- 326) Whitsett CF, Stulting RD: The distribution of HLA antigens on human corneal tissue. *Invest Ophthalmol Vis Sci* 1984;25:519-524.
- 327) Wiederholt M, Kossendrup D, Schulz W, Hoffmann F. Pharmacokinetic of topical cyclosporin A in the rabbit eye. *Invest Ophthalmol Vis Sci*. 1986;27:519-24.
- 328) Williams KA, Coster DJ: Clinical and experimental aspects of corneal transplantation. *Transplantation Rev* 1993;7:44-64.
- 329) Williams KA, Muehlberg M, Lewis RF et al.: How successful is corneal transplantation? A report from the Australian Corneal Graft Register. *Eye* 1995; 9:219-227.
- 330) Wolfe JH, Sands MS, Barker JE: Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell transfer. *Nature* 1992;360:749-753.
- 331) Wollensak G, Green WR: Analysis of sex-mismatched human corneal transplants by fluorescence in situ hybridization of the sex-chromosomes. *Exp Eye Res* 1999;68:341-346.

- 332) Wotherspoon AC, Hardman LS, Isaacson PG: Mucosa-associated lymphoid tissue (MALT) in the human conjunctiva. *J Pathol* 1994;174:33-37.
- 333) Xie H, Chen J, Lin Y, Liu Y, Ye C: Effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren's ulcer. *Chung Hua Yen Ko Tsachoih* 2002;38:13-15.
- 334) Xu L, Mango RL, Sands MS, Haskins ME, Ekkinwood NM, Ponder KP: Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. *Mol Therapy* 2002;6:745-758.
- 335) Yamagami S, Dana MR: The critical role of lymph nodes in corneal alloimmunization and graft rejection. *Invest Ophthalmol Vis Sci* 2001;42:1293-1298.
- 336) Yamagami S, Tsuru T, Ohkawa T, Endo H, Isobe M: Suppression of allograft rejection with anti-alpha beta T cell receptor antibody in rat corneal transplantation. *Transplantation* 1999;67:600-604.
- 337) Yatoh S, Kawakami Y, Imai M et al.: Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. *Transplantation* 1998;66:1519-1524.
- 338) Young E, Stark WJ, Predergast RA: Immunology of corneal allograft rejection: HLA-DR antigens on human corneal cells. *Invest Ophthalmol Vis Sci* 1985;26:571-576.
- 339) Yu WZ, Li XX, She HC et al.: Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. *Ophthalmic Res* 2003;35:239-246.
- 340) Zhang EP, Müller A, Schulte F et al.: Minimizing the side effects of ballistic gene transfer into the murine corneal epithelium. *Graefes Arch Clin Exp Ophthalmol* 2002;240:114-119.
- 341) Zhang EP, Schulte F, Bulfone-Paus S, Hoffmann F: The effect of corticosteroid and cyclosporin A on murine corneal allograft rejection. *Graefes Arch Clin Exp Ophthalmol* 2000;238:525-530.
- 342) Zhang EP, Franke J, Schroff M, Junghans C, Wittig B, Hoffmann F: Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. *Graefes Arch Clin Exp Ophthalmol* 2003;241:921-926.
- 343) Zhu C, Zhang Y, Pardridge WM: Widespread expression of an exogenous gene in the eye after intravenous administration. *Invest Ophthalmol Vis Sci* 2002;43:3075-3080.

- 344) Zierhut M, Stubiger N, Aboalchamat W, Landenberger H, Bialasiewicz AA, Engelmann K: Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis. *Ophthalmologie* 2001;98:647-651.
- 345) Zirm E: Eine erfolgreiche totale Keratoplastik. *Albrecht von Graefes Arch Ophthalmol* 1906;64:580-593.